Wird sie wieder Sqeezen CELL Therapeutics????? - 500 Beiträge pro Seite

[printguru]

Heutiger Schlußkurs an der Nasdaq 0,4425$ sollten morgen die 0,5$ gleich fallen könnte es passieren wie Anfangs 2009 damals ging es von ca 0,4$ auf fast 2,5$ und das in wenigen Tagen nach der letzten News vom Montag geht es auch nurmehr steil nach oben und das Volumen wird von Tag zu Tag größer sind hier Spieler alla Conergy am Werk die einen ordentlichen Sqeeze erzwingen wollen?

Wenn ja sollte man dabeisen ich jedenfalls bin heute zu Handelsende an der Nasdaq eingestiegen.

ich stelle gleich die News rein dann macht euch selber ein Bild.

Lg Printi

[printguru]

Originally published Tuesday, March 15, 2011 at 5:46 PM




Cell Therapeutics acquires rights to potential drug
Seattle-based Cell Therapeutics said it acquired exclusive marketing and co-development rights in North, Central and South America for the...

By Seattle Times staff

Related
Seattle-based Cell Therapeutics said it acquired exclusive marketing and co-development rights in North, Central and South America for the drug candidate tosedostat, developed by Chroma Therapeutics.

Tosedostat is an oral therapy for treatment of blood-related and other cancers. Cell Therapeutics, working with U.K.-based Chroma, will start a phase III clinical study of the drug in elderly patients with relapsed or refractory acute myeloid leukemia for potential approval by U.S. and European drug regulators

Cell Therapeutics will make an upfront payment of $5 million and a milestone payment of $5 million when the AML trial is initiated, expected in the fourth quarter.



http://seattletimes.nwsource.com/html/businesstechnology/201…

[printguru]

I first initiated research on Cell Therapeutics (Nasdaq: CTIC) on January 21, 2011, at $0.38 just prior to a price beat-down to $0.21 per share. Noting the solid institution interest, I was surprised to witness the rapid decline triggered by a security purchase agreement to sell up to $25 million of its shares by the next report on March 3.

Over the last several days, things have turned around rapidly for this little biotech. Let’s take a closer look at the company to find out why. Cell Therapeutics is a Seattle, Washington-based biopharmaceutical company that develops, acquires and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a phase III single-agent clinical trial product for the treatment of non-Hodgkins lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a phase III clinical trial product for the treatment of ovarian, esophageal and non-small cell lung cancer; and brostallicin, a phase I/II clinical trials product for the treatment of sarcoma. The company also has licensing and collaboration agreements with the giant pharmaceutical company, Novartis International (NYSE: NVS) .

On Monday, the company revealed that it will be spending $10 million to acquire the rights for an anti cancer drug owned by Chroma Therapeutics. Chroma’s drug has shown significant anti tumor responses in both blood related cancers and solid tumors. This news sent Cell Therapeutics soaring higher back to the January levels of $0.37 per share.

Will this move continue higher? Well, with the acquisition of the new drug and products back in the pipeline for FDA approval, Cell Therapeutics has a multi pronged chance of greatness. With this said, it’s important to also understand the risk and only invest with money you can afford to lose. Good trading!


Tagged as: Biotechnology stock, CTIC, NVS, Pharmaceutical Stock, therapeutics



Read more: http://www.beaconequity.com/cell-therapeutics-biotech-on-the…

[printguru]

US1509345039

viel Glück

[printguru]

nachbörslich geht es auch weiter nach oben...

gute Nacht

[printguru]

0,458$......

für Trader wird es morgen ein interessanter Tag

[printguru]

Sieht nicht schlecht aus in Italien wo ja der Haupthandelsplatz ist stehtder Kurs aktuell bei 0,334€=0,469$ bei EXTREM hohen Umsätzen.

Wenn alles klappt eröffnen wir heute an der Nasdaq so um die 0,48-0,52$ schön wäre ein schneller Anstieg bis auf 0,6$ es fehlen noch gut 25% bis dahin ist aber machbar

[printguru]

gelaufen bis 0,555$ nicht schlecht.

aber es scheint hier doch niemanden zu interessieren............